Christiaan Mulder

Senior Epidemiologist

Christiaan Mulder is a senior epidemiologist with a PhD in Epidemiology and 15 years of experience designing and leading epidemiological research (cost-effectiveness, diagnostic accuracy, and intervention studies), and supporting and training health staff in data collection and management and statistical data analysis.

Christiaan has undertaken extensive research on TB diagnostics, contact tracing and TB control and is an expert the implementation of short tuberculosis preventive treatment (TPT) regimens, optimising treatment delivery models, developing evidence-based guidelines, algorithms and monitoring and evaluation systems for capturing key treatment indicators, and health economic modelling.

Within KNCV, Christiaan is the chair of the KNCV Task Force Research and Epidemiology and technical lead on the Unitaid-funded IMPAACT4TB project, overseeing the implementation of TPT regimen in Ethiopia, Indonesia, Malawi, and Tanzania. Christiaan supports countries with the implementation of new treatment regimens, developing monitoring and evaluation systems, and conducting qualitative and mixed-methods research, including feasibility and acceptability studies for new TB drugs and regimens, service delivery models, and COVID-19 self-testing. Christiaan also provides technical assistance for the design and implementation of drug resistance surveys, optimal screening and diagnostic algorithms (including Xpert MTB/RIF and CAD4TB) and supports National TB Programs with the development of National Strategic Plans based on the ‘people- centred framework for tuberculosis programme planning and prioritization’.

Recent publications

Salazar-Austi N, Mulder C, Hoddinott G, Ryckman T, Hanrahan CF, Velen K, Chimoyi L, Charalambous A, Chihota, VN. Preventive Treatment for Household Contacts of Drug-Susceptible Tuberculosis Patients. Pathogens 2022, 11(11), 1258 Abstract & full article

Mitiku P, Scholten JN, Getachew M, Mulder C. 3HP nearly doubled the uptake of TB preventive treatment among PLHIV newly initiated on ART in Ethiopia. IJTLD. 2022; No abstract available

Mulder C, Rupert S, Setiawan E, Mambetova E, Edo P, Sugiharto J, et al. Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis. BMJ Glob Health. 2022;7(1). Abstract & full article


read all the KNCV publications

KNCV has been fighting TB since its establishment in 1903. Over the past 120 years, the organization has acquired indispensable knowledge and experience in the field of effective TB prevention and care, resulting in pre-elimination in the Netherlands and significant contributions to global evidence generation, policy development and TB program implementation worldwide.

Our experts
KNCV governance framework and integrity
Our patroness
Partner with us

Tuberculosis is still one of the major causes of preventable death in the world and claims over 4000 lives a day, leading to over 1,5 million deaths a year.

Patient stories

The story of Abdurahim
The story of Fikeraddis
The story of Issayas
The story of Zarina
The story of Maxine
The story of Saanvi


De versie van de browser die je gebruikt is verouderd en wordt niet ondersteund.
Upgrade je browser om de website optimaal te gebruiken.